Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IDEXX LABORATORIES INC /DEIDXX · Entity 3057 | Executive Vice President | February 12, 2026 | March 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IDEXX LABORATORIES INC /DE
Report date February 12, 2026 · Filed March 04, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Qualified Stock Option (right-to-buy)SEC Table II · derivative / convertible security · Conversion / exercise price $617.20 · Expires 2036-02-11 | Direct | 13,667 |
Reported balance
After 2026-02-12 transaction · row 2
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 2 · 2026-02-12 · Grant · Acquired 13,667 · Balance 13,667 F2: This Amendment on Form 4/A (this 'Amendment') amends the Form 4 filed on February 17, 2026 (the 'Original Form 4') solely to correct an administrative error, which resulted in the inadvertent erroneous reporting of the equity awards granted to the reporting person on February 12, 2026. Specifically, Table II of the Original Form 4 incorrectly reported that 6,319 restricted stock units (of which 1,580 restricted stock units were deferred) were granted to the reporting person on February 12, 2026, which did not occur. Instead, as reported in this Amendment, a non-qualified stock option to purchase 13,667 shares of Issuer common stock and an incentive stock option to purchase 162 shares of Issuer common stock were granted to the reporting person on February 12, 2026, with an exercise price equal to the closing price of the Issuer's common stock on that day. This Amendment does make any other changes to the Original Form 4. F3: Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2027. |
| Incentive Stock Option (right-to-buy)SEC Table II · derivative / convertible security · Conversion / exercise price $617.20 · Expires 2036-02-11 | Direct | 162 |
Reported balance
After 2026-02-12 transaction · row 3
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 3 · 2026-02-12 · Grant · Acquired 162 · Balance 162 F2: This Amendment on Form 4/A (this 'Amendment') amends the Form 4 filed on February 17, 2026 (the 'Original Form 4') solely to correct an administrative error, which resulted in the inadvertent erroneous reporting of the equity awards granted to the reporting person on February 12, 2026. Specifically, Table II of the Original Form 4 incorrectly reported that 6,319 restricted stock units (of which 1,580 restricted stock units were deferred) were granted to the reporting person on February 12, 2026, which did not occur. Instead, as reported in this Amendment, a non-qualified stock option to purchase 13,667 shares of Issuer common stock and an incentive stock option to purchase 162 shares of Issuer common stock were granted to the reporting person on February 12, 2026, with an exercise price equal to the closing price of the Issuer's common stock on that day. This Amendment does make any other changes to the Original Form 4. F4: Grant of option to buy shares of Issuer common stock that becomes exercisable in one installment on February 14, 2030. |
| Common StockSEC Table I · non-derivative | Direct | 15,092.351 |
Reported balance
Holding disclosure · report date 2026-02-12 · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · Balance 15,092.351 F1: Includes 184 vested but deferred restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 184 vested but deferred restricted stock units.
F2: This Amendment on Form 4/A (this 'Amendment') amends the Form 4 filed on February 17, 2026 (the 'Original Form 4') solely to correct an administrative error, which resulted in the inadvertent erroneous reporting of the equity awards granted to the reporting person on February 12, 2026. Specifically, Table II of the Original Form 4 incorrectly reported that 6,319 restricted stock units (of which 1,580 restricted stock units were deferred) were granted to the reporting person on February 12, 2026, which did not occur. Instead, as reported in this Amendment, a non-qualified stock option to purchase 13,667 shares of Issuer common stock and an incentive stock option to purchase 162 shares of Issuer common stock were granted to the reporting person on February 12, 2026, with an exercise price equal to the closing price of the Issuer's common stock on that day. This Amendment does make any other changes to the Original Form 4.
F3: Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2027.
F4: Grant of option to buy shares of Issuer common stock that becomes exercisable in one installment on February 14, 2030.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 13, 2025 Filed Feb 19, 2025 02:42 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantIncentive Stock Option (right-to-buy) · Derivative | 217 | $0.00 Strike: $459.76 | $0.00 |
DisclosureSEC source: 0000874716-25-000022 · wk-form4_1739932962.xml · derivative · entry 7 Erickson Michael G · CIK 0002005385 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 217 Underlying: Common Stock · 217 shares Expires 2035-02-12 F2 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in one installment on February 14, 2029. Read SEC document |
| February 13, 2025 Filed Feb 19, 2025 02:42 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 6,320 | $0.00 Strike: $459.76 | $0.00 |
DisclosureSEC source: 0000874716-25-000022 · wk-form4_1739932962.xml · derivative · entry 6 Erickson Michael G · CIK 0002005385 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,320 Underlying: Common Stock · 6,320 shares Expires 2035-02-12 F1 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2026. Read SEC document |
| February 11, 2025 Filed Feb 12, 2025 22:04 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionIncentive Stock Option (right-to-buy) · Derivative | 1,544 | Not disclosed Strike: $67.85 | Not disclosed |
DisclosureSEC source: 0000874716-25-000008 · wk-form4_1739397872.xml · derivative · entry 2 Erickson Michael G · CIK 0002005385 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,544 shares Expires 2026-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Not applicable. F1 · derivative.exercise_date: Grant of option to buy 1,544 shares of Issuer common stock that vested on February 14, 2021. Read SEC document |
| February 11, 2025 Filed Feb 12, 2025 22:04 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 1,544 | $67.85 | $104,760.40 |
DisclosureSEC source: 0000874716-25-000008 · wk-form4_1739397872.xml · nonDerivative · entry 1 Erickson Michael G · CIK 0002005385 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,836.3617 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:54 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 95 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000034 · wk-form4_1708124083.xml · derivative · entry 14 Erickson Michael G · CIK 0002005385 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 282 Underlying: Common Stock · 95 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock and vest in four annual installments beginning on February 14, 2024. F8 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vest in four annual installments beginning on February 14, 2024. F8 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vest in four annual installments beginning on February 14, 2024. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:54 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 93 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000034 · wk-form4_1708124083.xml · derivative · entry 13 Erickson Michael G · CIK 0002005385 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 185 Underlying: Common Stock · 93 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments beginning on February 14, 2023. F7 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments beginning on February 14, 2023. F7 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments beginning on February 14, 2023. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:54 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 69 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000034 · wk-form4_1708124083.xml · derivative · entry 12 Erickson Michael G · CIK 0002005385 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69 Underlying: Common Stock · 69 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer. common stock and vest in four annual installments beginning on February 14, 2022. F6 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer. common stock and vest in four annual installments beginning on February 14, 2022. F6 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer. common stock and vest in four annual installments beginning on February 14, 2022. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:54 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 97 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000034 · wk-form4_1708124083.xml · derivative · entry 11 Erickson Michael G · CIK 0002005385 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 97 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock and vested in four annual installments beginning on February 14, 2021. F5 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vested in four annual installments beginning on February 14, 2021. F5 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vested in four annual installments beginning on February 14, 2021. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:54 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 108 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000034 · wk-form4_1708124083.xml · derivative · entry 10 Erickson Michael G · CIK 0002005385 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 108 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock and vesedt in five annual installments beginning on February 14, 2020. F4 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vesedt in five annual installments beginning on February 14, 2020. F4 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vesedt in five annual installments beginning on February 14, 2020. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:54 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantRestricted Stock Unit · Derivative | 1,204 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000034 · wk-form4_1708124083.xml · derivative · entry 9 Erickson Michael G · CIK 0002005385 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,204 Underlying: Common Stock · 1,204 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock and vest in four annual installments beginning on February 14, 2025. F3 · derivative.exercise_date: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock and vest in four annual installments beginning on February 14, 2025. F3 · derivative.expiration_date: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock and vest in four annual installments beginning on February 14, 2025. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:54 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantIncentive Stock Option (right-to-buy) · Derivative | 178 | $0.00 Strike: $560.56 | $0.00 |
DisclosureSEC source: 0000874716-24-000034 · wk-form4_1708124083.xml · derivative · entry 8 Erickson Michael G · CIK 0002005385 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 178 Underlying: Common Stock · 178 shares Expires 2034-02-13 F2 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in one installment on February 14, 2028. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:54 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 5,407 | $0.00 Strike: $560.56 | $0.00 |
DisclosureSEC source: 0000874716-24-000034 · wk-form4_1708124083.xml · derivative · entry 7 Erickson Michael G · CIK 0002005385 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,407 Underlying: Common Stock · 5,407 shares Expires 2034-02-13 F1 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2025. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:54 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Tax withholdingCommon Stock | 144 | $560.56 | $80,720.64 |
DisclosureSEC source: 0000874716-24-000034 · wk-form4_1708124083.xml · nonDerivative · entry 6 Erickson Michael G · CIK 0002005385 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,657.3617 Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:54 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 95 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000034 · wk-form4_1708124083.xml · nonDerivative · entry 5 Erickson Michael G · CIK 0002005385 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,801.3617 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:54 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 93 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000034 · wk-form4_1708124083.xml · nonDerivative · entry 4 Erickson Michael G · CIK 0002005385 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,706.3617 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:54 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 69 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000034 · wk-form4_1708124083.xml · nonDerivative · entry 3 Erickson Michael G · CIK 0002005385 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,613.3617 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:54 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 97 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000034 · wk-form4_1708124083.xml · nonDerivative · entry 2 Erickson Michael G · CIK 0002005385 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,544.3617 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:54 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 108 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000034 · wk-form4_1708124083.xml · nonDerivative · entry 1 Erickson Michael G · CIK 0002005385 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,447.3617 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.